STIM
Neuronetics, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$2.02+24.69%
Price as of Jul 20, 2026
STIM financials
Neuronetics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $149.2M | $74.9M | $71.3M | $65.2M |
| Cost of revenue | $76.8M | $20.7M | $19.6M | $15.5M |
| Gross profit | $72.3M | $54.2M | $51.7M | $49.7M |
| Operating expenses | $103.7M | $88.7M | $82.3M | $84.8M |
| Operating income | -$31.4M | -$34.6M | -$30.6M | -$35.1M |
| Net income | -$39.0M | -$43.7M | -$30.2M | -$37.2M |
| EBITDA | -$27.1M | -$34.4M | -$22.8M | -$32.0M |
| Basic EPS | $-0.59 | $-1.38 | $-1.05 | $-1.38 |
| Diluted EPS | $-0.59 | $-1.38 | $-1.05 | $-1.38 |
| Balance sheet | ||||
| Cash & equivalents | $34.1M | $19.5M | $59.7M | $70.3M |
| Total assets | $141.6M | $140.9M | $115.8M | $116.9M |
| Total liabilities | $115.3M | $109.1M | $81.6M | $59.8M |
| Stockholders’ equity | $22.4M | $27.7M | $34.2M | $57.1M |
| Total debt | $90.3M | $82.6M | $62.5M | $39.7M |
| Net debt | $56.2M | $63.2M | $2.8M | -$30.6M |
| Cash flow | ||||
| Operating cash flow | -$20.4M | -$31.0M | -$32.0M | -$30.7M |
| Capital expenditure | -$801.0K | -$1.5M | -$2.4M | -$3.3M |
| Free cash flow | -$21.2M | -$32.5M | -$34.4M | -$34.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |